Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.32 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.32 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491912 | 0.76 | ORAI1 (0.37) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL1429795 | 0.70 | TRPV6 (0.41) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL15577145 | 0.70 | TRPV6 (0.41) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL1138975 | 0.68 | ALDH1A1 (0.42) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL28745155 | 0.66 | TRPV6 (0.37) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL28745277 | 0.66 | ORAI1 (0.37) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL1226528 | 0.65 | TRPV6 (0.44) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL15570627 | 0.65 | TRPV6 (0.44) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL117263 | 0.64 | ALDH1A1 (0.45) | CA4CA6CA5ACA7ENPP2 | |
| Ethylene Glycol SCHEMBL28307523 | 0.64 | ENPP2 (0.42) | CA4CA6CA5ACA7ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210790-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | THE JOHNS HOPKINS UNIVERSTY | 2023-07-06 | — | — | US | claimed |
| EP-4157998-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | The Johns Hopkins University (US) | 2023-04-05 | — | — | EP | claimed |
| EP-3344232-B1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | UNIV MCMASTER (CA) | 2022-01-26 | — | — | EP | claimed |
| US-10611908-B2 | Micelles for mucoadhesive drug delivery | MCMASTER UNIVERSITY (CA) | 2020-04-07 | — | — | US | claimed |
| US-20180265694-A1 | Micelles for Mucoadhesive Drug Delivery | MCMASTER UNIVERSITY (CA) | 2018-09-20 | — | — | US | claimed |
| EP-3344232-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | Mcmaster University (CA) | 2018-07-11 | — | — | EP | claimed |
| WO-2017035656-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | MCMASTER UNIVERSITY (CA) | 2017-03-09 | — | — | WO | claimed |
| US-20240229131-A1 | TRANSITION-METAL CATALYST COMPOSITIONS AND METHODS FOR SEQUENCING BY SYNTHESIS | ILLUMINA, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024145154-A1 | METHODS OF SEQUENCING USING 3´ ALLYL BLOCKED NUCLEOTIDES | ILLUMINA, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240218443-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | ILLUMINA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | ILLUMINA, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240182963-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | ILLUMINA, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20230210790-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | THE JOHNS HOPKINS UNIVERSTY | 2023-07-06 | — | — | US | disclosed |
| EP-2986666-A1 | METHOD OF MANUFACTURING NON-FIRED TYPE ELECTRODE | E. I. du Pont de Nemours and Company (US) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014172137-A1 | METHOD OF MANUFACTURING NON-FIRED TYPE ELECTRODE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140306165-A1 | METHOD OF MANUFACTURING NON-FIRING TYPE ELECTRODE | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-10-16 | — | — | US | disclosed |
| US-7038070-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2006-05-02 | — | — | US | disclosed |
| US-6963017-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| US-20050033076-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2005-02-10 | — | — | US | disclosed |
| US-20030009046-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033076-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP2J2, IDH3A | CA4 4167/4885CA6 3014/4885CA5A 3044/4885 |
| US-20240182963-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | NT5C3B, RNGTT, ALKBH1 | CA4 2300/4885CA6 2289/4885CA5A 1555/4885 |
| US-20030009046-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP1B1, CYP1A1 | CA4 4047/4885CA6 2951/4885CA5A 3066/4885 |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | RNGTT, NT5C3B, NSUN2 | CA4 3724/4885CA6 3531/4885CA5A 1925/4885 |
| US-20230210790-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | EPX, EPCAM, ELANE | CA4 3103/4885CA6 2295/4885CA5A 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.